A commissioning policy is a document that defines access to a service for a particular group of patients.

A NICE technology appraisal guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate.

These are important documents that are developed to ensure consistency in access to treatments nationwide.

• Abatacept for autoimmune complications of primary immunodeficiencies caused by CTLA-4 or LRBA genetic mutation (aged 2 years and over)
• Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)
• Abatacept for refractory idiopathic inflammatory myopathies (adults and children aged 2 years and over)
• Abiraterone acetate and prednisolone for high-risk, hormone sensitive, non-metastatic prostate cancer (adults)
• Allogeneic haematopoietic stem cell transplantation (Allo-HSCT) for adult transfusion dependent thalassaemia
• Allogeneic haematopoietic stem cell transplantation for adults with sickle cell disease
• Allogeneic haematopoietic stem cell transplant for patients with X-linked cerebral adrenoleukodystrophy (adults)
• Allogeneic haematopoietic stem cell transplant for primary immunodeficiencies (all ages)
• Anakinra to treat periodic fevers and autoinflammatory diseases (all ages)
• Anakinra for haemophagocytic lymphohistiocytosis for adults and children in all ages
• Arsenic trioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)
• Auditory brainstem implant with congential abnomalities of the auditory nerves of cochleae
• Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (all ages)
• Baricitinib for use in monogenic interferonopathies (adults and children 2 years and over)
• Bedaquiline (B), pretomanid (Pa), linezolid (L) +/- moxifloxacin (M) (BPaLM/BPaL) for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB or pre-extensively drug resistant (pre-XDR) TB
• Bendamustine with rituximab for first line treatment of advanced indolent non-Hodgkin’s lymphoma (all ages)
• Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages)
• Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)
• Bictegravir-emtricitabine-tenofovir alafenamide for the treatment of HIV-1 in adults
• Bone anchored hearing aids
• Bone conducting hearing implants for hearing loss (all ages)
• Bone morphogenic protein-2 for spinal fusion
• Brachytherapy dose escalation with external beam radiotherapy for intermediate- and high-risk localised prostate cancer
• [BVB] Combination brentuximab vedotin and bendamustine for patients aged 8 years and above with relapsed or refractory classical Hodgkin lymphoma
• Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)
• Cervical disc replacement for cervical radiculomyelopathy
• Cholic acid and chenodeoxycholic acid for treating inborn errors of bile acid synthesis (all ages)
• Clinical commissioning policy: Catheter ablation for paroxysmal and persistent atrial fibrillation (adults)
• Commissioning medicines for children in specialised services
• Complex endovascular stent grafts in abdominal aortic aneurysm
• Cytoreductive surgery for patients with peritoneal carcinomatosis
• Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer
• Dabrafenib for BRAFV600E mutation positive histiocytic neoplasms where standard care has failed (all ages)
• Deep brain stimulation in movement disorders
• Defibrotide for severe veno-occlusive disease following stem cell transplant
• Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
• Dialysis away from base
• Direct skeletal fixation for transfemoral limb loss (adults)
• Disease modifying therapies for patients with multiple sclerosis
• Dolutegravir for treatment of HIV-1 infection (all ages)
• Dolutegravir-rilpivirine for treating HIV-1 in adults
• Doravirine for the treatment of HIV-1 in adults
• Eculizumab in the treatment of recurrence of C3 glomerulopathy post-kidney transplant (all ages)
• Elvitegravir/cobicistat/emtricitabine/tenofovir for treatment of HIV in adults
• Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors
• Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)
• Emicizumab for prophylaxis of bleeding episodes in people with moderate haemophilia A without inhibitors (all ages)
• External beam radiotherapy for patients presenting with hormone sensitive, low volume metastatic prostate cancer at the time of diagnosis
• Extracorporeal membrane oxygenation (ECMO) as abridge to lung transplant (all ages)
• [Fampridine] Prolonged-released (PR) fampridine as a treatment of adults with multiple sclerosis and associated walking impairment
• Fostemsavir for multi-drug resistant HIV-1 infection (adult)
• Fresh osteochondral allograft for osteochondral lesions of the knee in adults and post-pubescent children
• Gemcitabine and capecitabine following surgery for pancreatic cancer (all ages)
• Gemcitabine and paclitaxel albumin combination chemotherapy for the treatment of locally advanced non-metastatic pancreatic cancer (adults)
• Genetic testing for BRCA1 and BRCA2 mutations
• Glucarpidase for the urgent treatment of methotrexate-induced renal dysfunction
• Haematopoietic stem cell transplantation (HSCT) (all ages)
• Haematopoietic stem cell transplantation for lymphoplasmacytic lymphoma (adults)
• Hand and upper limb reconstruction using vascularised composite allotransplantation
• Human coagulation factor X for hereditary factor X deficiency (all ages)
• Human normal immunoglobulin for preventative treatment of idiopathic systemic capillary leak syndrome following an acute episode (adults)
• Human normal immunoglobulin for treatment of scleromyxedema (adults)
• Hyperbaric oxygen therapy for decompression illness/gas embolism
• Hypofractionated external beam radiotherapy for the treatment of localised prostate cancer
• Immediate antiretroviral therapy for treatment of HIV-1 in adults and adolescents
• Immune tolerance induction for haemophilia A (all ages)
• Icatibant for treatment of moderate to severe acute swellings due to bradykinin-mediated angioedema with normal C1 inhibitor
• Inhaled therapy for adults and children with cystic fibrosis
• Intrathecal Baclofen
• Intrathecal pumps for treatment of severe cancer pain
• Intravenous (6 years and above) and subcutaneous (adolescents and adults) C1 esterase inhibitor injections for routine prophylaxis of hereditary angioedema type I and II or acquired angioedema
• Keratoprosthesis for corneal blindness (all ages)
• Lanreotide as a monotherapy for the treatment of symptomatic non-localised autosomal dominant polycystic liver disease (adults)
• Left atrial appendage occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults)
• Lenacapavir for multi-drug resistant human immunodeficiency virus 1 infection (adults)
• Levodopa-carbidopa intestinal gel (LCIG) and levodopa-carbidopa-entacapone intestinal gel (LECIG) for Parkinson’s disease (adults)
• Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (adults)
• Lomitapide for treating homozygous familial hypercholesterolaemia (adults)
• Lonafarnib for Hutchinson-Gilford progeria syndrome (12 months of age and over)
• Lung volume reduction by surgery or endobronchial valve for severe emphysema in adults
• Management of fetal anaemia secondary to red cell alloimmunisation (fetal transfusion)
• Management of twin to twin syndrome
• Maternal intravenous immunoglobulin for the prevention of allo-immune fetal and neonatal haemochromatosis
• Mecasermin for treatment of growth failure
• Mechanical thrombectomy for acute ischaemic stroke (all ages)
• [Mercaptamine] Delayed-release mercaptamine bitartrate for patients with nephropathic cystinosis (Age > 1 years)
• Mercaptamine hydrochloride viscous eyedrops for corneal cystine deposits in people aged 2 years and over
• Metreleptin for congenital leptin deficiency (all ages)
• Microprocessor controlled prosthetic knees
• MR-guided laser interstitial thermal therapy for treatment of epileptogenic zones in children and adults with refractory focal epilepsy
• Multi-grip prosthetic hand (all ages)
• Nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex refractory to current treatment options (adults and post pubescent children)
• Obesity surgery for children with severe complex obesity
• Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults)
• Occipital nerve stimulation for adults with intractable chronic migraines and medically refractory chronic cluster headaches
• Palliative radiotherapy for bone pain
• Pasireotide: an injectable medical therapy for the treatment of Cushing’s disease
• Pegvisomant for acromegaly as a third-line treatment (adults)
• [Pembrolizumab] Neo-adjuvant followed by adjuvant pembrolizumab for stage III macroscopic resectable melanoma (12 years and older)
• Penile prostheses for end stage erectile dysfunction
• Percutaneous mitral valve leaflet repair for primary degenerative mitral regurgitation in adults
• Percutaneous patent foraman ovale closure for the prevention of recurrent cerebral embolic stroke in adults (around the age 60 years and under)
• Phrenic nerve pacing following spinal cord injury
• Plerixafor for stem cell mobilisation in adults and children
• Pre-implantation genetic diagnosis
• Prescribing of gender affirming hormones (masculinising or feminising hormones) as part of the children and young people’s gender service
• Prostate-Specific Membrane Antigen (PSMA) radiotracers in Positron Emission Tomography – Computed Tomography (PETCT) Imaging for individuals with high-risk primary or recurrent prostate cancer (adults)
• Proton beam therapy for children, teenagers and young adults in the treatment of malignant and non-malignant tumours
• Proton beam therapy for craniospinal irradiation in adults
• Proton beam radiotherapy (high energy) for skull base tumour treatment – NHS overseas programme (Adult)
• Radiotherapy after primary surgery for breast cancer
• Ranibizumab in retinopathy of prematurity
• Reimbursement of expenses for living donors
• Reimbursement for the use of generic drugs for pre exposure prophylaxis (PrEP) for the prevention of HIV
• Retreatment of chronic hepatitis C infection in adults with advanced or decompensated cirrhosis
• Riociguat for pulmonary arterial hypertension
• Robotic assisted surgery for kidney cancer
• Robotic assisted surgical procedures for prostate cancer
• Sacral nerve stimulation for faecal incontinence (Adult)
• Sacral nerve stimulation for overactive bladder
• Sapropterin for phenylketonuria (all ages)
• Sapropterin for phenylketonuria – use in pregnancy
• Second allogeneic haematopoietic stem cell transplant for relapsed disease (all ages)
• Selective dorsal rhizotomy for the treatment of spasticity in cerebral palsy (children aged 3-9 years)
• Selective internal radiation therapy for chemotherapy refractory intolerant metastatic colorectal cancer (adults)
• Selexipag for treating pulmonary arterial hypertension (adults)
• Serum eye drops for the treatment of severe ocular surface disease (all ages)
• Sildenafil and bosentan for the treatment of digital ulceration in systemic sclerosis
• Siltuximab for idiopathic multicentric Castleman disease (adults)
• Sirolimus in extracranial slow-flow vascular malformations refractory to standard therapies
• Sodium oxybate for symptom control of narcolpesy with cataplexy (children and adolescents aged 7 until 19 years)
• Stereotactic ablative body radiotherapy for non-small-cell lung cancer (adults)
• Stereotactic ablative radiotherapy for hepatocellular carcinoma (adults)
• Stereotactic ablative radiotherapy for patients with metachronous extracranial oligometastatic cancer (all ages)
• Stereotactic ablative radiotherapy for patients with previously irradiated, locally recurrent primary pelvic tumours (all ages)
• Stereotactic ablative radiotherapy for the treatment of localised prostate cancer (adults)
• Stereotactic ablative body radiotherapy for patients with localised, non-metastatic, renal cancer who are medically unfit for surgery (adults)
• Stereotactic radiosurgery/radiotherapy for cavernous venous malformations (cavernomas)
• Stereotactic radiosurgery/radiotherapy for cerebral metastases
• Stereotactic radiosurgery/radiotherapy for epedymoma, haemangioblastoma, pilocytic astrocytoma and trigeminal schwannoma
• Stereotactic/radiosurgery radiotherapy for glomus tumours (skull base paragangliomas, glomus jugulare tumours)
• Stereotactic radiosurgery/radiotherapy for meningioma
• Stereotactic radiosurgery/radiotherapy for the treatment of pituitary adenomas
• Stereotactic radiosurgery/radiotherapy for vestibular schwannoma and other cranial nerve neuromas
• Stereotactic radiosurgery for cerebral arteriovenous malformations
• Stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) to the surgical cavity following resection of cerebral metastases (All ages)
• Stereotactic radiosurgery for trigeminal neuralgia
• Stereotactic radiosurgery for essential tremor refractory to medication (adults)
• Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease
• Surgical sperm retrieval for male infertility
• Susoctocog alfa for treating bleeding episodes in people with acquired haemophilia A (all ages)
• Targeted therapies for pulmonary hypertension functional class II
• Targeted therapies for use in pulmonary hypertension in adults
• Temozolomide as adjuvant treatment for people with newly diagnosed anaplastic astrocytoma without 1p/19q codeletion following surgery and radiotherapy (adults)
• Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents
• Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)
• Tocilizumab for Takayasu arteritis
• Tocilizumab for the treatment of adult-onset Still’s disease refractory to second-line therapy (adults)
• Tolvaptan for hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormona in patients requiring cancer chemotherapy
• Total pancreatectomy with islet auto transplant for chronic pancreatitis (adults)
• Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)
• Transcatheter aortic value implantation
• Transcranial magnetic resonance guided focused ultrasound thalamotomy for treatment of medication-refractory essential tremor (effective from 1 April 2021)
• Treatment as prevention in HIV infected adults
• Treatment of acute attacks in hereditary angiodema (adult)
• Treatment of chronic Hepatitis C in patients with cirrhosis
• Treatment of iron overload for transfused and non transfused patients with chronic inherited anaemias
• Treatment of iron overload for transfused and non-transfused patients with chronic inherited anaemias (all ages)
• Treatments for graft versus host disease following haematopoietic stem cell transplantation
• Trientine for Wilson disease (all ages)
• Urethroplasty for benign urethral strictures in adult men
• Vagal nerve stimulation for epilepsy
• Vismodegib for adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas. (Adults)
• [Vismodegib] Neoadjuvant vismodegib for locally advanced basal cell carcinoma (BCC) prior to curative treatment for lesions likely to result in functional sequelae or significant aesthetic sequelae (Adults)
• Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease